Xu J.-H.,First Peoples Hospital of Shenyang |
Li X.-F.,Transfusion Medicine Institute |
Li X.-F.,Key Laboratory of Blood Safety Research of Liaoning |
Li X.-F.,Key Laboratory of Blood Safety Research of Shenyang
Chinese Journal of Tissue Engineering Research | Year: 2015
BACKGROUND: Hematopoietic stem cell transplantation is an important means for clinical cure of hematologic malignancies, congenital hereditary diseases and autoimmune diseases. Although ABO-incompatibility has no effects on the survival of transplanted hematopoietic stem cells, the transfusion strategy to ABO-incompatible grafts in allogeneic hematopoietic stem cell transplantation is worth studying. OBJECTIVE: To explore the antigen-antibody changes during blood conversion after ABO-incompatible hematopoietic stem cell transplantation as well as transfusion strategies. METHODS: Blood grouping, antibody detection, antibody titer determination, cross-match test were employed for antigen-antibody monitoring during blood conversion and pre-transfusion compatibility detection in 24 cases undergoing ABO-incompatible allogeneic hematopoietic stem cell transplantation. Another 30 cases undergoing ABO-compatible allogeneic hematopoietic stem cell transplantation were enrolled as controls to select the appropriate blood. RESULTS AND CONCLUSION: All of the 24 ABO-incompatible patients developed the hematopoietic reconstitution after transplantation, but both major and major-minor ABO incompatibility were different from ABO compatibility in the time of erythrocytic recovery (P < 0.05). According to the changes of ABO antigen and antibody during the blood conversion, the patients of major ABO incompatibility were selected the red blood cells of their own type, the patients of minor ABO incompatibility were selected the red blood cells of the blood group from patients to donors gradually, and the patients of major-minor ABO incompatibility were selected the red blood cells from O-type blood to donor’s type gradually. None of the 24 recipients presented hemolytic reaction during transplantation and after transfusion. Therefore, the transfusion strategy to ABO-incompatible grafts in allogeneic hematopoietic stem cell transplantation is dynamically varied according to the changes of patient’s ABO antigen and antibody, and evaluating the recovery of erythropoietic system can guide blood component selection, avoid hemolytic transfusion reaction, and insure the safety of hematopoietic stem cell transplantation. © 2015 Journal of Clinical Rehabilitative Tissue Engineering Research. All rights reserved.
Lin R.P.,First Peoples Hospital of Shenyang |
Yao C.Y.,Shenyang University |
Ren D.X.,First Peoples Hospital of Shenyang
Genetics and Molecular Research | Year: 2015
Several previous studies indicated that genetic polymorphisms in inflammatory factor genes were associated with glioma risk. However, the relationship between the prostaglandin-endoperoxide synthase 2 (PTGS2) genetic polymorphism and glioma remains unclear in the Chinese population. We selected 199 histologically confirmed adult glioma patients and 199 cancer-free controls for the present study and analyzed the distribution of the PTGS2 genotypes and haplotypes. We found that the CC+CT genotype of rs5275 was common in the control group but not in the glioma group (P = 0.033). In addition, we found that the frequency of the C allele was higher in the control group than in the glioma group (P = 0.014). For rs6681231, although we found no significant difference between the 2 groups in genotype distribution, we found that the frequency of the C allele was lower in glioma patients than in control subjects (P = 0.044). We found no significant difference between these 2 groups in the rs689466 genotype and allele distributions. Haplotype analysis suggested that the frequency of the C-A-C haplotype was significantly lower in glioma patients than in control subjects [P = 0.028, odds ratio (OR) = 0.628, 95% confidence interval (CI) = 0.413-0.955]. However, the frequency of the T-A-G haplotype was higher in glioma patients than in control subjects (P = 0.036, OR = 1.418, 95%CI = 1.022-1.967). Therefore, polymorphisms in the PTGS2 gene may be associated with glioma susceptibility in the Chinese population. © FUNPEC-RP.